Title: Neogenomics Inc (NEO) 10K Annual Reports & 10Q SEC Filings
URL: https://last10k.com/sec-filings/neo

HOME


LOGIN


PREMIUM


FREE TRIAL


SEC FILINGS


STOCK SCREENERS


EARNINGS


TRENDING


STOCKTWITS


INSIDER TRADING


SENTIMENT ANALYSIS


MANAGER PORTFOLIOS


LATE CORPORATE NEWS






				 



Neogenomics Inc (NEO) SEC Filing 10-K Annual Report for the fiscal year ending Sunday, December 31, 2023


Home
SEC Filings
Neogenomics Inc (NEO)
10-K Annual Report Tue Feb 20 2024






SEC Filings



 
NEO Valuations





Intrinsic Value





Financial Stability





Financial Ratios





Insider Trades





Manager Portfolios





Notifications





 
NEO Annual Reports
				  





10-K Annual Report February 2024


PDF

PDF


Select PDF Feature:
Include Exhibits
Highlight YoY Changes
Highlight Sentiment

10-K Only


Word
Excel
CSV


Table of Contents
Business
Risk Factors
Unresolved Staff Comments
Cybersecurity
Properties
Legal Proceedings
Mine Safety Disclosures
Market for Registrants Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Managements Discussion and Analysis of Financial Condition and Results of Operations
Quantitative and Qualitative Disclosures About Market Risk
Financial Statements and Supplementary Data
Changes in and Disagreements With Accountants on Accounting and Financial Disclosure
Controls and Procedures
Other Information
Disclosure Regarding Foreign Jurisdictions That Prevent Inspections
Directors, Executive Officers and Corporate Governance
Executive Compensation
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Certain Relationships and Related Transactions, and Director Independence
Principal Accounting Fees and Services
Exhibits and Financial Statement Schedules
Form 10K Summary
SIGNATURES








									10-K Annual Report February 2023																






									10-K Annual Report February 2022																






									10-K Annual Report February 2021																






									10-K Annual Report February 2020																






									10-K Annual Report February 2019																






									10-K Annual Report March 2018																






									10-K Annual Report March 2017																






									10-K Annual Report March 2016																






NEO Quarterly Reports
				  





									10-Q Quarterly Report July 2024																






									10-Q Quarterly Report April 2024																






									10-Q Quarterly Report November 2023																






									10-Q Quarterly Report August 2023																






									10-Q Quarterly Report May 2023																






									10-Q Quarterly Report November 2022																






									10-Q Quarterly Report August 2022																






									10-Q Quarterly Report May 2022																






									10-Q Quarterly Report November 2021																






									10-Q Quarterly Report August 2021																






NEO Corporate News
				  





									Earnings ReleaseFinancial Exhibit																	July 2024







									Vote of Security Holders																	May 2024







									Earnings ReleaseFinancial Exhibit																	April 2024







									Event for Officers																	April 2024







									Event for Officers																	February 2024







									Earnings ReleaseFinancial Exhibit																	February 2024







									Earnings ReleaseFinancial Exhibit																	November 2023







									Earnings ReleaseFinancial Exhibit																	August 2023







									Event for OfficersFinancial ExhibitRegulated Disclosure																	June 2023







									Vote of Security Holders																	May 2023













Last10K.com | 10-K Annual Report Tue Feb 20 2024






Neogenomics Inc


													CIK: 1077183
																										Ticker: NEO




Earnings Press Release
 10-K Annual Report
 10-K YoY Changes
 Annual Proxy




Neogenomics Inc

HISTORY
TOOLS


CIK: 1077183
Ticker: NEO




Exhibit 99.1NeoGenomics Reports Fourth Quarter and Full Year 2023 ResultsFourth Quarter Revenue Increased 12% to $156 million; Full Year Revenue Increased 16% to $592 million Fort Myers, Florida, (February 20, 2024) - NeoGenomics, Inc. (Nasdaq: NEO) (the “Company”), a leading provider of oncology testing and global contract research services, today announced fourth quarter and full year 2023 results for the period ended December 31, 2023.Highlights•Fourth quarter consolidated revenue increased 12% to $156 million; Full year consolidated revenue increased 16% to $592 million•Fourth quarter Clinical Services revenue increased 20% to $130 million; Full year Clinical Services revenue increased 18% to $496 million•Fourth quarter Advanced Diagnostics revenue decreased 17% to $25 million; Full year Advanced Diagnostics revenue increased 6% to $96 million•Fourth quarter net loss decreased 37% to $14 million; Full year net loss decreased 39% to $88 million•Fourth quarter Adjusted EBITDA was positive $9 million, an increase of $11 million; Full year Adjusted EBITDA was positive $3 million, an increase of $51 million“NeoGenomics’ fourth quarter and full year 2023 results show the momentum and strength of our business as we continued to deliver long-term, sustainable growth on our way to becoming the leading oncology laboratory,” said Chris Smith, CEO of NeoGenomics. “We believe 2024 will be an exciting year as we continue to invest in our people and technologies to support consistent revenue growth and profitability, while allowing us to better serve our patients and providers.”Fourth Quarter ResultsConsolidated revenue for the fourth quarter of 2023 was $156 million, an increase of 12% over the same period in 2022. Clinical Services revenue of $130 million was an increase year-over-year of 20%. Clinical test volume(1) increased by 6% year-over-year. Average revenue per clinical test (“revenue per test”) increased by 13% to $441. Advanced Diagnostics revenue decreased by 17% to $25 million compared to the fourth quarter of 2022.Consolidated gross profit for the fourth quarter of 2023 was $67.6 million, an increase of 18.9% compared to the fourth quarter of 2022. This increase was primarily due to an increase in revenue. Consolidated gross profit margin, including amortization of acquired intangible assets, was 43.5%. Adjusted Gross Profit Margin(2), excluding amortization of acquired intangible assets, was 46.7%.Operating expenses for the fourth quarter of 2023 were $86 million, an increase of $3 million, or 4%, compared to the fourth quarter of 2022. This increase primarily reflects an increase in professional fees, an increase in payroll and payroll-related costs, including non-cash stock-based compensation expense, and an increase in travel expenses. This increase was partially offset by a decrease in recruiting expenses and a decrease in credit card fees.Net loss for the quarter was $14 million compared to net loss of $23 million for the fourth quarter of 2022.NeoGenomics, Inc.  |  9490 NeoGenomics Way Fort Myers, FL 33912The following information was filed by Neogenomics Inc (NEO) on Tuesday, February 20, 2024 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release. 

Please wait while we load the requested 10-K report or click the link below:https://last10k.com/sec-filings/report/1077183/000107718324000011/neo-20231231.htm


View differences made from one year to another to evaluate Neogenomics Inc's financial trajectory





Sample 10-K Year-over-Year (YoY) Comparison



Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Neogenomics Inc.

Continue







Assess how Neogenomics Inc's management team is paid from their Annual Proxy





Screenshot example of actual Proxy Statement




Neogenomics Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2024 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors


Continue














SEC Filing Tools




 Sentiment
 Sections
 Exhibits
 Stats


 



 Rating					
Learn More










Filter Sentiment:



All






Positive




Negative





Filter Category:




All





Financial







Revenue






M & A






Legal






Other






Filter Subcategory:




All






Expense






Income






Product






Geography






Cash Flow






Shares





Earnings







Other







 Inside Neogenomics Inc's 10-K Annual Report:


 Other - Other   Highlight
Widely reported inflation has occurred, however, and may be ongoing for the foreseeable future.



 Other - Other   Highlight
Depending on the severity and persistence of these inflationary pressures, we could experience, in the future, a negative impact on our financial results.

 Other - Other   Highlight
Summary of Significant Accounting Policies, to our Consolidated Financial Statements for a complete description of our significant accounting policies.

 Financial - Expense   Highlight
Such qualitative factors included macroeconomic conditions, industry and market considerations, cost factors, overall financial performance and other relevant events.

 Financial - Income   Highlight
The increase in interest income in 2023 was due to the higher interest rate environment experienced when compared to the same period in 2022.

 Revenue - Product
Increases in Clinical Services revenue...Read more

 Financial - Expense
Operating needs include, but are...Read more

 Other - Other
Restructuring charges relate to a...Read more

 Revenue - Product
Revenue is recognized when, or...Read more

 Other - Other
Our critical accounting policies are...Read more

 Other - Other
We believe that we are...Read more

 M & A - Other
The assumptions and estimates, including...Read more

 Other - Other
We have funded and plan...Read more

 Other - Other
We anticipate research and development...Read more

 Other - Other
We expect our molecular laboratory...Read more

 Other - Other
a non-competitive partner to community-based...Read more

 Other - Other
We accrue contingent losses when...Read more

 Financial - Expense
Restructuring charges consist of severance...Read more

 Revenue - Product
The performance obligation is satisfied...Read more

 Other - Other
These diagnostic services are billed...Read more

 Financial - Expense
We believe lower cost and...Read more

 Other - Other
The laboratory biomarker tests that...Read more

 Other - Other
on helping to bring more...Read more

 Other - Other
The primary reason for the...Read more

 Financial - Expense
The cash provided by financing...Read more

 Legal - Other
Contingent losses are recorded based...Read more

 Other - Other
The increase is primarily due...Read more

 Revenue - Product
We forecast capital expenditures in...Read more

 Other - Other
The clinical cancer testing services...Read more

 M & A - Other
The acquisition of Inivata provided...Read more

 Other - Other
NeoGenomics, Inc., a Nevada corporation...Read more

 Financial - Expense
Research and development expenses are...Read more

 Other - Other
InVisionFirst®-Lung is a highly sensitive,...Read more

 Other - Other
In the second quarter of...Read more

 Other - Other
In these instances we will...Read more

 Other - Other
In certain instances, larger clinician...Read more

 Other - Other
We are continuously enhancing and...Read more

 Other - Other
In addition, we offer molecular-only...Read more

 Other - Other
Collection of consideration we expect...Read more

 Other - Other
Our Advanced Diagnostics segment provides...Read more

 Other - Other
We typically serve these types...Read more

 Other - Other
Our Advanced Diagnostics team can...Read more

 Other - Other
We also support our pathology...Read more

 Revenue - Product
To date, we have financed...Read more

 Other - Other
We will continue to work...Read more

 Other - Other
Advances in science and technology...Read more

 Other - Other
For Clinical Services, our specialized...Read more

 Other - Other
Our Advanced Diagnostics segment supports...Read more

 Other - Other
These diagnostic tools and therapies...Read more

 Other - Other
Implicit price concessions represent differences...Read more

 Other - Other
We closely monitor changes in...Read more

 Other - Other
Our medical team often advises...Read more

 Other - Other
The FDA is currently considering...Read more

 Other - Other
We also offer testing and...Read more

 Other - Other
If the carrying value is...Read more

 Other - Other
We have a broad Molecular...Read more

 Financial - Expense
Research and development expenses relate...Read more

 Other - Other
year ended December 31, 2023,...Read more

 Other - Other
We are able to offer...Read more

 Other - Other
Fair Value Measurements in the...Read more

 Other - Other
NGS panels are one of...Read more

 Other - Other
These comprehensive panels can allow...Read more

 Other - Other
This ability helps to speed...Read more

 Other - Other
The quantitative analysis is performed...Read more

 Other - Other
In 2017 the FDA shifted...Read more

 Other - Other
In carrying out these commitments,...Read more

 Other - Other
Accordingly, we performed a quantitative...Read more

 Other - Other
We currently anticipate that our...Read more

 Other - Other
As a leading global oncology...Read more

 Other - Other
This portion of our business...Read more

 Other - Other
As a result, we anticipate...Read more

 Financial - Expense
We also allocate professional services,...Read more

 Other - Other
We are continuing to develop...Read more

 Other - Other
This is attractive to our...Read more

 Other - Other
We help our customers develop...Read more

 Other - Other
As studies unfold, our clinical...Read more

 Other - Other
In carrying out these commitments,...Read more

 Revenue - Product
We will continue to expand...Read more

 Other - Other
Assets are not presented at...Read more

 Other - Other
The VALID Act was expected...Read more

 Financial - Expense
In the third quarter of...Read more

 Revenue - Product
We expect our sales and...Read more

 Other - Other
We are continuing to develop...Read more

 Financial - Expense
Cost of revenue includes compensation...Read more

 Revenue - Geography
We expect these charges will...Read more

 Financial - Income
We estimate the fair values...Read more

 Financial - Income
We determined the fair values...Read more

 Other - Other
While we anticipate an increasingly...Read more

 Other - Other
On October 1, 2023, we...Read more

 Other - Other
If management concludes that it...Read more

 Other - Other
Trapelo™ is an end-to-end, clinical...Read more

 Other - Other
We remain optimistic about our...Read more

 Financial - Cash Flow
using discounted cash flows and...Read more

 Other - Other
We first assess qualitative factors...Read more

 Other - Other
In 2018 the FDA began...Read more

 Other - Other
Cash used in operating activities...Read more

 Other - Other
This comprehensive menu means that...Read more

 Other - Other
Whether serving as the single...Read more

 Other - Other
Restructuring activities are ongoing and...Read more

 Other - Other
In other pre-clinical and non-clinical...Read more

 Other - Other
The most recent such proposal,...Read more

 Other - Other
As a result of the...Read more

 Other - Other
During the year ended December...Read more

 Revenue - Geography
The Company operates a network...Read more

 Financial - Income
For the year ended December...Read more

 Other - Other
We also work on developing...Read more

 Financial - Expense
This 4.4% increase is primarily...Read more

 Other - Other
During the year ended December...Read more

 Other - Other
Moving from discovery to development,...Read more

 Other - Other
Our management routinely makes judgments...Read more

 Financial - Expense
Consolidated cost of revenue increased...Read more

 Financial - Shares
As a result of the...Read more

 Financial - Expense
General and administrative expenses consist...Read more

 Other - Other
These tests are interpreted by...Read more

 Financial - Expense
The increase primarily reflects increases...Read more

 Revenue - Product
Revenue is recorded for all...Read more

 Financial - Expense
This decrease is primarily due...Read more

 Financial - Expense
We expect higher commissions expense...Read more

 Revenue - Product
We do not anticipate significant...Read more

 Other - Other
The results of the quantitative...Read more

 Other - Other
We have structured departmental goals...Read more

 Other - Other
During the years ended December...Read more

 Revenue - Product
Moreover, our team of MDs...Read more

 Other - Other
Each trial we support comes...Read more

 Other - Other
If some amount within a...Read more

 Other - Other
Results of Operations for the...Read more

 Financial - Expense
We will invest in information...Read more

 Financial - Earnings
The decrease in cash used...Read more

 Other - Other
However, recent agency announcements made...Read more

 Other - Other
At this time, we cannot...Read more

 Other - Other
We evaluate goodwill on an...Read more

 Other - Other
As of June 30, 2022,...Read more

 Other - Other
Accounts receivable are reported for...Read more

 Other - Other
When no amount within the...Read more



 
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report





Audit Information





Cover Page





Consolidated Balance Sheets





Consolidated Balance Sheets (Parenthetical)





Consolidated Statements Of Cash Flows





Consolidated Statements Of Comprehensive Loss





Consolidated Statements Of Operations





Consolidated Statements Of Stockholders??? Equity





Commitment And Contingencies (Tables)





Commitment And Contingencies - Narrative (Details)





Commitments And Contingencies





Commitments And Contingencies - Schedule Of Purchase Commitments (Details)





Debt





Debt (Tables)





Debt - Narrative (Details)





Debt - Schedule Of Long Term Debt (Details)





Debt - Schedule Of Maturities Of Long Term Debt (Details)





Defined Contribution Plan





Defined Contribution Plan (Details)





Equity Transactions





Equity Transactions (Details)





Fair Value Measurements





Fair Value Measurements (Tables)





Fair Value Measurements - Schedule Of Fair Value, Assets Measured On Recurring And Nonrecurring Basis (Details)





Fair Value Measurements - Schedule Of Fair Value, Assets Measured On Recurring Basis (Details)





Fair Value Measurements - Schedule Of Investments Classified By Contractual Maturity Date (Details)





Goodwill And Intangible Assets





Goodwill And Intangible Assets (Tables)





Goodwill And Intangible Assets - Schedule Of Amortization Expense (Details)





Goodwill And Intangible Assets - Schedule Of Classes Of Intangible Assets (Details)





Goodwill And Intangible Assets - Schedule Of Estimated Amortization Expense (Details)





Goodwill And Intangible Assets - Schedule Of Goodwill (Details)





Income Taxes





Income Taxes (Tables)





Income Taxes - Narrative (Details)





Income Taxes - Schedule Of Components Of Income Tax Expense (Benefit) (Details)





Income Taxes - Schedule Of Deferred Tax Assets And Liabilities (Details)





Income Taxes - Schedule Of Effective Income Tax Rate Reconciliation (Details)





Income Taxes - Schedule Of Unrecognized Tax Benefits (Details)





Leases





Leases (Tables)





Leases - Narrative (Details)





Leases - Schedule Of Additional Supplemental Data (Details)





Leases - Schedule Of Future Minimum Lease Payments (Details)





Nature Of Business





Net Loss Per Share





Net Loss Per Share (Tables)





Net Loss Per Share - Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share (Details)





Net Loss Per Share - Schedule Of Earnings Per Share, Basic And Diluted (Details)





Property And Equipment, Net





Property And Equipment, Net (Tables)





Property And Equipment, Net - Narrative (Details)





Property And Equipment, Net - Schedule Of Depreciation (Details)





Property And Equipment, Net - Schedule Of Property And Equipment (Details)





Related Party Transactions





Related Party Transactions (Details)





Restructuring





Restructuring (Tables)





Restructuring - Narrative (Details)





Restructuring - Schedule Of Restructuring Activities (Details)





Revenue Recognition





Revenue Recognition (Tables)





Revenue Recognition - Narrative (Details)





Revenue Recognition - Schedule Of Contract Assets And Liabilities (Details)





Revenue Recognition - Schedule Of Disaggregation Of Revenue (Details)





Segment Information





Segment Information (Tables)





Segment Information - Narrative (Details)





Segment Information - Schedule Of Segment Information (Details)





Stock-Based Compensation





Stock-Based Compensation (Tables)





Stock-Based Compensation - Narrative (Details)





Stock-Based Compensation - Schedule Of Fair Value Of Each Stock Option Award Granted (Details)





Stock-Based Compensation - Schedule Of Restricted Stock Activity (Details)





Stock-Based Compensation - Schedule Of Stock Option Activity (Details)





Summary Of Significant Accounting Policies





Summary Of Significant Accounting Policies (Details)





Summary Of Significant Accounting Policies (Policies)




 
Material Contracts, Statements, Certifications & more
Neogenomics Inc provided additional information to their SEC Filing as exhibits





Exhibit 21.1: Subsidaries Of The Registrant





Exhibit 23.1: Consents Of Experts And Counsel





Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification





Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification





Exhibit 32.1: Section 1350 Certification





Exhibit 97.1: Ex-97.1






Ticker: NEO CIK: 1077183
Form Type: 10-K Annual Report
Accession Number: 0001077183-24-000011
Submitted to the SEC: Tue Feb 20 2024 4:23:05 PM EST
Accepted by the SEC: Tue Feb 20 2024
Period:  Sunday, December 31, 2023
Industry: Testing Laboratories						
External Resources:
 Stock Quote
 Social Media
 SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/neo/0001077183-24-000011.htm








About 
											Contact 
											Help 
											API 
											Privacy 
											Terms 
									


© 2012 - 2024 Last10K.com All Rights Reserved









×
You're Signed Out
Sign in for the full experience


Sign in
Join Now








Intrinsic Value Calculator








Screenshot of intrinsic value for AT&T (2019)




Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not
Continue












Never Miss A New SEC Filing Again








Screenshot taken from Gmail for a new 10-K Annual Report




Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news
Continue












We Highlighted This SEC Filing For You








Screenshot taken from Wynn's 2018 10-K Annual Report




Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q
Continue












Widen Your SEC Filing Reading Experience








Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report




Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view
Continue












Uncover Actionable Information Inside SEC Filings








Screenshot taken from Lumber Liquidators 10-K Annual Report




Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q
Continue












Adobe PDF, Microsoft Word, Excel and CSV Downloads








Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats




Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe Acrobat (PDF), Microsoft Word (DOCX), Excel (XLSX) and Comma-Delimited (CSV) files for offline viewing, annotations and analysis
Continue












Adobe PDF, Microsoft Word, Excel and CSV Downloads








Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats




Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe Acrobat (PDF), Microsoft Word (DOCX), Excel (XLSX) and Comma-Delimited (CSV) files for offline viewing, annotations and analysis
Continue












Financial Stability Report








Screenshot of financial stability report for Coco-Cola (2019)




Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity
Continue












Get a Better Picture of a Company's Performance








Available Financial Ratios




Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years
Continue












See when company executives buy or sell their own stock








Screenshot taken from Euronet (EEFT)




Last10K.com Member Feature

Use our calculated cost dollar values to discover when and how much registered owners BUY, SELL or excercise their company stock OPTIONS aggregated from Form 4 Insider Transactions SEC Filings
Continue












See how institutional managers trade a stock








Screenshot taken from General Motors (GM)




Last10K.com Member Feature

View which hedge funds, pension / retirement funds, endowments, banks and insurance companies have increased or decreased their positions in a particular stock. Includes Ownership Percent, Buy versus Sell comparison, Put-Call ratio and more
Continue












FREE Financial Statements








Screenshot of actual balance sheet from company 10-K Annual Report




Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports
Continue for FREE












SEC Filing Exhibit
 PDF Download



Loading SEC Filing Exhibit...








SEC Filing Financial Summary
 PDF Download
 Excel Download



Loading SEC Filing Financial Summary...

